GlassScriptPhysician profile
Tayfun M Ozgen
NPI 1780671818
$3,779.69
in general payments reported to CMS, 2019-2025
24 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $79.89 · 2021: $582 · 2022: $248 · 2023: $526 · 2024: $1,052 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $585.34 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $486.91 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $471.98 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $360.05 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.66 | 2019-2024 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals LP | $320.50 | 2021-2024 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $222.92 | 2025 | Symbravo |
| Lilly USA, LLC | $204.43 | 2023-2025 | Mounjaro, Jardiance |
| Allergan, INC. | $129.49 | 2019 | |
| Amarin Pharma, INC. | $126.19 | 2019 | |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Pfizer INC. | $95.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.06 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $44.95 | 2022-2023 | Quviviq |
| Abbott Laboratories | $34.27 | 2024 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.57 | 2019 | |
| Merck Sharp & Dohme LLC | $23.78 | 2019-2021 | |
| Dexcom, INC. | $20.53 | 2019 | |
| Shire North American Group INC | $19.36 | 2019 | |
| Astellas Pharma US INC | $18.21 | 2023 | Veozah |
| Exact Sciences Corporation | $17.34 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $16.79 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $14.08 | 2019 | |
| Currax Pharmaceuticals LLC | $13.95 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayfun Ozgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.